Table 4.

PSM patients' intraoperative and postoperative data

	PSH (n = 266)	NON-PSH (n = 266)	P Value
Morbidity≥1	68(25)	91(34)	0.04
Morbidity >Dindo IIIA, n(%)	27(10)	45(16)	0.03
Non-surgical morbidity, n(%)	37(13)	42(15)	0.62
Pulmonary	26(10)	37(13)	0.17
Cardiac	4(2)	5(2)	1
Sepsis	9(3)	3(1)	0.11
Vascular	9(3)	4(2)	0.26
Acute renal failure	0	2(1)	0.49
Surgical morbidity, n(%)	49(18)	59(22)	0.33
Deep collection	47(17)	57(21)	0.33
Wound infection	7(3)	3(1)	0.34
Liver failure	5(2)	19(7)	0.006
Biliary fistula	10(4)	17(6)	0.23
Reoperation, n(%)	16(6)	13(5)	0.74
Mortality (90 days), n(%)	2(1)	3(1)	1
Intensive care unit stay, days, [median, (range)]	0(0–1)	0(0–8)	0.004
Total hospitalization, days, [median, (range)]	11(7–36)	11(7–47)	0.85
R1 liver metastasis resection, n(%)	85(32)	75(28)	0.57
Adjuvant chemotherapy	175(66)	33(50)	0.001
Recurrence, n(%)	166(62)	160(60)	0.68
Liver-only recurrence, n(%)	79(30)	59(22)	0.06
Liver recurrence treatment
Re-hepatectomy, n(%)	25(22)	17(29)	0.86
Radiofrequency, n(%)	7(9)	3(5)	0.51
Other, n(%)	47(59)	39(66)	0.74

The bold values are considered statistically significant values.